Guess Who Picked Bellerophon Therapeutics Inc. (NASDAQ:BLPH) Shares

0
10
Thermometer Temperature Influenza Flu Fever

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Bellerophon Therapeutics Inc. (NASDAQ:BLPH) reported that Cvi Investments, Inc. has picked up 2,000,000 of common stock as of 2017-05-18.

The acquisition brings the aggregate amount owned by Cvi Investments, Inc. to a total of 2,000,000 representing less than 5.7% stake in the company.

For those not familiar with the company, Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company’s second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company’s BCM is in PRESERVATION I clinical trial.

A glance at Bellerophon Therapeutics Inc. (NASDAQ:BLPH)’s key stats reveals a current market capitalization of 44.00 Million based on 32.99 Million shares outstanding and a price at last close of $1.41 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-12-09, Luehring picked up 20,000 at a purchase price of $0.56. This brings their total   holding to 39,860 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Bellerophon Therapeutics Inc. (NASDAQ:BLPH) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.